Obesity drug that is a GLP-1 agonist
FDA determined on December 19, 2024 that the tirzepatide injection shortage was resolved, and on February 21, 2025 that the semaglutide injection shortage was resolved
Accordingly, it is reported that glutamate supplementation of up to 1-2 mM enhanced IFNy and IL-10 secretion by activated adult human peripheral T cells in vitro , whereas secretion of T H 2 cytokines IL-4 and IL-5 was unaffected (180)
Consult your doctor immediately if these side effects persist or worsen
Key takeaways MeAgain is the GLP-1 food tracker app where every meal connects to dose timing, appetite changes, protein, fiber, water, side effects, weight, and progress not just calories
Click below to schedule your appointment online, or call 623-334-4000 to speak with our friendly team.